Minerva Biotechnologies Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
Minerva Biotechnologies is a clinical-stage biotechnology company based in Waltham, Massachusetts, focused on immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. Its lead program, huMNC2-CAR44, is a CAR-T therapy targeting a MUC1-related receptor and is being evaluated in its first-in-human trial for metastatic breast cancer. The company is expanding this trial to include a second CAR-T product intended to improve cellular persistence, and it maintains a broader pipeline that also includes next-generation CAR-T products, an antibody therapy, and a small-molecule treatment for metastasis.